Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adj...

Full description

Bibliographic Details
Authors: Fernández-Martínez, Aranzazu, Albanell Mestres, Joan, Martin, Miquel
Format: article
Status:Published version
Publication Date:2017
Country:España
Institution:Universitat Pompeu Fabra
Repository:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/35067
Online Access:http://hdl.handle.net/10230/35067
http://dx.doi.org/10.18632/oncotarget.15748
Access Level:Open access
Keyword:Mama -- Càncer
Estrògens -- Receptors
Ki67
PAM50/Prosigna
Breast cancer
Estrogen receptor-positive/HER2-negative
id ES_5a64efef62dbcd885da01d3f60bdd160
oai_identifier_str oai:repositori.upf.edu:10230/35067
network_acronym_str ES
network_name_str España
repository_id_str
spelling Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancerFernández-Martínez, AranzazuAlbanell Mestres, JoanMartin, MiquelMama -- CàncerEstrògens -- ReceptorsKi67PAM50/ProsignaBreast cancerEstrogen receptor-positive/HER2-negativePAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%.Impact Journals201820182017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/35067http://dx.doi.org/10.18632/oncotarget.15748reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésOncotarget. 2017 Mar 28;8(13):21930-7Copyright : © 2017 Fernández-Martinez et al. This article is distributed under the terms of the https://creativecommons.org/licenses/by/3.0/ (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.https://creativecommons.org/licenses/by/3.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/350672026-06-12T07:21:37Z
dc.title.none.fl_str_mv Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
title Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
spellingShingle Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
Fernández-Martínez, Aranzazu
Mama -- Càncer
Estrògens -- Receptors
Ki67
PAM50/Prosigna
Breast cancer
Estrogen receptor-positive/HER2-negative
title_short Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
title_full Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
title_fullStr Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
title_full_unstemmed Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
title_sort Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
dc.creator.none.fl_str_mv Fernández-Martínez, Aranzazu
Albanell Mestres, Joan
Martin, Miquel
author Fernández-Martínez, Aranzazu
author_facet Fernández-Martínez, Aranzazu
Albanell Mestres, Joan
Martin, Miquel
author_role author
author2 Albanell Mestres, Joan
Martin, Miquel
author2_role author
author
dc.subject.none.fl_str_mv Mama -- Càncer
Estrògens -- Receptors
Ki67
PAM50/Prosigna
Breast cancer
Estrogen receptor-positive/HER2-negative
topic Mama -- Càncer
Estrògens -- Receptors
Ki67
PAM50/Prosigna
Breast cancer
Estrogen receptor-positive/HER2-negative
description PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/35067
http://dx.doi.org/10.18632/oncotarget.15748
url http://hdl.handle.net/10230/35067
http://dx.doi.org/10.18632/oncotarget.15748
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Oncotarget. 2017 Mar 28;8(13):21930-7
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/3.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/3.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Impact Journals
publisher.none.fl_str_mv Impact Journals
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408693716516864
score 15,811543

Similar Items